omeprazole has been researched along with Disease Exacerbation in 22 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This prospective randomised study aimed to investigate whether H pylori eradication can influence gastritis and its sequelae during long term omeprazole therapy for gastro-oesophageal reflux disease (GORD)." | 9.11 | Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. ( Dent, J; Festen, HP; Goldfain, D; Havu, N; Klinkenberg-Knol, EC; Kolkman, JJ; Kuipers, EJ; Lamm, M; Nelis, GF; Snel, P; Walan, A; Zeitoun, P, 2004) |
| "Stress induced gastric ulcer is a serious health problem in diabetic patients." | 5.48 | Hesperidin protects against stress induced gastric ulcer through regulation of peroxisome proliferator activator receptor gamma in diabetic rats. ( Abd El Motteleb, DM; Elshazly, SM; Ibrahim, IAAE, 2018) |
| " This prospective randomised study aimed to investigate whether H pylori eradication can influence gastritis and its sequelae during long term omeprazole therapy for gastro-oesophageal reflux disease (GORD)." | 5.11 | Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. ( Dent, J; Festen, HP; Goldfain, D; Havu, N; Klinkenberg-Knol, EC; Kolkman, JJ; Kuipers, EJ; Lamm, M; Nelis, GF; Snel, P; Walan, A; Zeitoun, P, 2004) |
| "Two hundred and forty-three patients received rabeprazole (20 mg or 10 mg) or omeprazole (20 mg) once daily for up to 5 years, for gastro-oesophageal reflux disease and 51% completed the whole 5 year period." | 5.11 | Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. ( Fiocca, R; Jacobs, A; Miller, N; Morocutti, A; Rindi, G; Thjodleifsson, B, 2005) |
| "A diagnosis of toxic epidermal necrolysis (TEN) was made." | 2.45 | Toxic epidermal necrolysis and neutropaenia: complications of omeprazole. ( Burke, A; Burns, A; Handfield-Jones, S; Palmer, M; Sinha, A; Thakor, AS, 2009) |
| " Methods to optimize nocturnal acid control include careful attention to dosing schedule, using higher doses of PPIs, adding an histamine H2-receptor antagonist at bedtime to once or twice daily delayed-release PPI, or using immediate-release omeprazole (Zegerid powder for oral suspension; Santarus, Inc." | 2.43 | Review article: putting immediate-release proton-pump inhibitors into clinical practice--improving nocturnal acid control and avoiding the possible complications of excessive acid exposure. ( Katz, PO, 2005) |
| "Stress induced gastric ulcer is a serious health problem in diabetic patients." | 1.48 | Hesperidin protects against stress induced gastric ulcer through regulation of peroxisome proliferator activator receptor gamma in diabetic rats. ( Abd El Motteleb, DM; Elshazly, SM; Ibrahim, IAAE, 2018) |
| "pylori eradication prevented gastric cancer to the greatest extent when antibiotics are given at an early point of infection, but that eradication therapy given at a later time point delayed the development of severe dysplastic lesions." | 1.35 | Helicobacter pylori eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. ( Fox, JG; Ge, Z; Lee, CW; Rickman, B; Rogers, AB; Wang, TC, 2008) |
| "Those ascribed to gastroesophageal reflux and vocal abuse have a high resolution rate, although some cases need rescue procedures." | 1.30 | Clinical evolution of laryngeal granulomas: treatment and prognosis. ( De Biase, NG; de Lima Pontes, PA; Gadelha, EC, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 14 (63.64) | 29.6817 |
| 2010's | 5 (22.73) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Guedes, JVM | 1 |
| Aquino, JA | 1 |
| Castro, TLB | 1 |
| Augusto de Morais, F | 1 |
| Baldoni, AO | 1 |
| Belo, VS | 1 |
| Otoni, A | 1 |
| Elshazly, SM | 1 |
| Abd El Motteleb, DM | 1 |
| Ibrahim, IAAE | 1 |
| Okamoto, T | 1 |
| Hatakeyama, S | 1 |
| Hosogoe, S | 1 |
| Tanaka, Y | 1 |
| Imanishi, K | 1 |
| Takashima, T | 1 |
| Saitoh, F | 1 |
| Suzuki, T | 1 |
| Ohyama, C | 1 |
| Goldstein, JL | 1 |
| Scheiman, JM | 1 |
| Fort, JG | 1 |
| Whellan, DJ | 1 |
| Thakor, AS | 1 |
| Burke, A | 1 |
| Handfield-Jones, S | 1 |
| Sinha, A | 1 |
| Palmer, M | 1 |
| Burns, A | 1 |
| Lord, RV | 1 |
| Miyashita, T | 1 |
| Shah, FA | 1 |
| Harmon, JW | 1 |
| Marti, GP | 1 |
| Matsui, D | 1 |
| Okamoto, K | 1 |
| Makino, I | 1 |
| Hayashi, H | 1 |
| Oyama, K | 1 |
| Nakagawara, H | 1 |
| Tajima, H | 1 |
| Fujita, H | 1 |
| Takamura, H | 1 |
| Murakami, M | 1 |
| Ninomiya, I | 1 |
| Kitagawa, H | 1 |
| Fushida, S | 1 |
| Fujimura, T | 1 |
| Ohta, T | 1 |
| Kuipers, EJ | 1 |
| Nelis, GF | 1 |
| Klinkenberg-Knol, EC | 1 |
| Snel, P | 1 |
| Goldfain, D | 1 |
| Kolkman, JJ | 1 |
| Festen, HP | 1 |
| Dent, J | 1 |
| Zeitoun, P | 1 |
| Havu, N | 1 |
| Lamm, M | 1 |
| Walan, A | 1 |
| Leung, WK | 1 |
| Lin, SR | 1 |
| Ching, JY | 1 |
| To, KF | 1 |
| Ng, EK | 1 |
| Chan, FK | 1 |
| Lau, JY | 1 |
| Sung, JJ | 1 |
| Rindi, G | 1 |
| Fiocca, R | 1 |
| Morocutti, A | 1 |
| Jacobs, A | 1 |
| Miller, N | 1 |
| Thjodleifsson, B | 1 |
| Chen, LT | 1 |
| Lin, JT | 1 |
| Tai, JJ | 1 |
| Chen, GH | 1 |
| Yeh, HZ | 1 |
| Yang, SS | 1 |
| Wang, HP | 1 |
| Kuo, SH | 1 |
| Sheu, BS | 1 |
| Jan, CM | 1 |
| Wang, WM | 1 |
| Wang, TE | 1 |
| Wu, CW | 1 |
| Chen, CL | 1 |
| Su, IJ | 1 |
| Whang-Peng, J | 1 |
| Cheng, AL | 1 |
| Katz, PO | 1 |
| Rossi, M | 1 |
| Barreca, M | 1 |
| de Bortoli, N | 1 |
| Renzi, C | 1 |
| Santi, S | 1 |
| Gennai, A | 1 |
| Bellini, M | 1 |
| Costa, F | 1 |
| Conio, M | 1 |
| Marchi, S | 1 |
| You, WC | 1 |
| Brown, LM | 1 |
| Zhang, L | 1 |
| Li, JY | 1 |
| Jin, ML | 1 |
| Chang, YS | 1 |
| Ma, JL | 1 |
| Pan, KF | 1 |
| Liu, WD | 1 |
| Hu, Y | 1 |
| Crystal-Mansour, S | 1 |
| Pee, D | 1 |
| Blot, WJ | 1 |
| Fraumeni, JF | 1 |
| Xu, GW | 1 |
| Gail, MH | 1 |
| Quigley, EM | 1 |
| Overholt, BF | 1 |
| Wang, KK | 1 |
| Burdick, JS | 1 |
| Lightdale, CJ | 1 |
| Kimmey, M | 1 |
| Nava, HR | 1 |
| Sivak, MV | 1 |
| Nishioka, N | 1 |
| Barr, H | 1 |
| Marcon, N | 1 |
| Pedrosa, M | 1 |
| Bronner, MP | 1 |
| Grace, M | 1 |
| Depot, M | 1 |
| Lee, CW | 1 |
| Rickman, B | 1 |
| Rogers, AB | 1 |
| Ge, Z | 1 |
| Wang, TC | 1 |
| Fox, JG | 1 |
| McDougall, NI | 1 |
| Johnston, BT | 1 |
| Kee, F | 1 |
| Collins, JS | 1 |
| McFarland, RJ | 1 |
| Love, AH | 1 |
| Brzozowski, T | 1 |
| Konturek, PC | 1 |
| Konturek, SJ | 1 |
| Drozdowicz, D | 1 |
| Kwiecieñ, S | 1 |
| Pajdo, R | 1 |
| Bielanski, W | 1 |
| Hahn, EG | 1 |
| de Lima Pontes, PA | 1 |
| De Biase, NG | 1 |
| Gadelha, EC | 1 |
| Watson, SA | 1 |
| Smith, AM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of Mucosa-associated Lymphoid Tissue Type of The Stomach[NCT00201422] | 70 participants (Actual) | Interventional | 1996-06-30 | Completed | |||
| A Phase II, Multi-Center Study of Interventional Spray Cryotherapy for Early-Stage Esophageal Cancer (ICE-CANCER)[NCT01868139] | 1 participants (Actual) | Interventional | 2013-06-30 | Terminated (stopped due to insufficient accrual) | |||
| Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study[NCT02081404] | 98 participants (Actual) | Interventional | 2009-03-01 | Completed | |||
| Impact of Weight Loss on Gastroesophageal Reflux Disease in Overweight and Obese Subjects: a Prospective Study[NCT01574573] | 52 participants (Actual) | Interventional | 2009-06-30 | Terminated (stopped due to Closed due to lack of recruitment) | |||
| A Randomized Controlled Trial Comparing Proton Pump Inhibitor Therapy With and Without Interarytenoid Botulinum Toxin Injection for Vocal Fold Granuloma[NCT01678053] | Phase 2 | 0 participants (Actual) | Interventional | 2012-09-30 | Withdrawn (stopped due to Was not able to recruit patients for randomization.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for omeprazole and Disease Exacerbation
| Article | Year |
|---|---|
Toxic epidermal necrolysis and neutropaenia: complications of omeprazole.
Topics: Acute Kidney Injury; Adult; Biopsy, Needle; Combined Modality Therapy; Diabetes Mellitus, Type 1; Di | 2009 |
Does antireflux surgery prevent progression of Barrett's esophagus?
Topics: Adenocarcinoma; Barrett Esophagus; Cohort Studies; Combined Modality Therapy; Disease Progression; E | 2011 |
Do proton pump inhibitors protect against cancer progression in GERD?
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Barrett Esop | 2013 |
Review article: putting immediate-release proton-pump inhibitors into clinical practice--improving nocturnal acid control and avoiding the possible complications of excessive acid exposure.
Topics: Adenocarcinoma; Barrett Esophagus; Chronotherapy; Delayed-Action Preparations; Disease Progression; | 2005 |
7 trials available for omeprazole and Disease Exacerbation
| Article | Year |
|---|---|
Aspirin Use in Secondary Cardiovascular Protection and the Development of Aspirin-Associated Erosions and Ulcers.
Topics: Adolescent; Adult; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Disease Progression; Dou | 2016 |
Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Disease Progression; Double- | 2004 |
Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication.
Topics: Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Disease Progression; Drug Therapy, Combination | 2004 |
Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Biopsy; Dis | 2005 |
Efficacy of Nissen fundoplication versus medical therapy in the regression of low-grade dysplasia in patients with Barrett esophagus: a prospective study.
Topics: Adult; Aged; Barrett Esophagus; Disease Progression; Enzyme Inhibitors; Esophagus; Female; Fundoplic | 2006 |
Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions.
Topics: Adult; Amoxicillin; Ascorbic Acid; China; Disease Progression; Double-Blind Method; Drug Therapy, Co | 2006 |
Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia.
Topics: Adenocarcinoma; Aged; Anti-Ulcer Agents; Barrett Esophagus; Biopsy; Combined Modality Therapy; Dihem | 2007 |
11 other studies available for omeprazole and Disease Exacerbation
| Article | Year |
|---|---|
Omeprazole use and risk of chronic kidney disease evolution.
Topics: Aged; Aged, 80 and over; Cohort Studies; Disease Progression; Female; Humans; Male; Middle Aged; Ome | 2020 |
Hesperidin protects against stress induced gastric ulcer through regulation of peroxisome proliferator activator receptor gamma in diabetic rats.
Topics: Animals; Antioxidants; Biomarkers; Blood Glucose; Body Weight; Cyclooxygenase 2; Diabetes Mellitus, | 2018 |
Proton pump inhibitor as an independent factor of progression of abdominal aortic calcification in patients on maintenance hemodialysis.
Topics: Aged; Aorta, Abdominal; Computed Tomography Angiography; Disease Progression; Esomeprazole; Female; | 2018 |
Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Disease Progression; Disease-Fre | 2005 |
Porfimer: new drug. Endobrachyesophagus: encouraging preliminary results.
Topics: Barrett Esophagus; Clinical Trials as Topic; Dihematoporphyrin Ether; Disease Progression; Humans; O | 2006 |
Getting categorical on GERD.
Topics: Anti-Ulcer Agents; Barrett Esophagus; Disease Progression; Esophageal Neoplasms; Esophagitis; Esopha | 2007 |
Helicobacter pylori eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice.
Topics: Animals; Anti-Infective Agents; Anti-Ulcer Agents; Carcinoma in Situ; Cell Proliferation; Clarithrom | 2008 |
Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Barrett Esophagus; Cisapride; Deglutition Disorders; Disea | 1996 |
Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Barrett Esophagus; Cisapride; Deglutition Disorders; Disea | 1996 |
Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Barrett Esophagus; Cisapride; Deglutition Disorders; Disea | 1996 |
Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Barrett Esophagus; Cisapride; Deglutition Disorders; Disea | 1996 |
Role of gastric acid secretion in progression of acute gastric erosions induced by ischemia-reperfusion into gastric ulcers.
Topics: Acute Disease; Animals; Anti-Ulcer Agents; Blood Flow Velocity; Disease Progression; Gastric Acid; G | 2000 |
Clinical evolution of laryngeal granulomas: treatment and prognosis.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Antiemetics; Botulinum Toxins, Type A; Combined Modality | 1999 |
Hypergastrinemia promotes adenoma progression in the APC(Min-/+) mouse model of familial adenomatous polyposis.
Topics: Adenoma; Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Animals; Bromodeoxyuridine; | 2001 |